Metabolomics in Healthcare: Unveiling Digital Solutions Driving Disease Diagnosis and Personalized Care.

Ekta Jain, PhD[1]; Shivangi Das, MSc[1]; Vandana Yadav, MS[1]; Stan Kachnowski, PhD, MPA[1]

[1]Healthcare Innovation and Technology Lab (HITLAB)

ABSTRACT

Metabolomics, fueled by advancements in digital technologies, is catalyzing a paradigm shift in healthcare by enhancing disease diagnosis and detection.
This analysis meticulously examines leading metabolomics solutions, delving into their functionalities, target demographics, funding sources, and investor profiles. It also scrutinizes the pivotal role these solutions play in detecting and diagnosing various diseases. Through insightful exploration, it identifies prevalent technologies, audience considerations, and thematic undercurrents, emphasizing the integration of technology, patient-centric approaches, and personalized care.
Moreover, a thorough thematic and content analysis of the features and functions of each solution highlights overarching key themes. This report serves as a distilled synthesis of intricate findings, presenting an overview of 27 digital solutions offered by companies primarily situated in the United States.

OBJECTIVE

- Identify and analyze market trends in the metabolomics digital solutions landscape.
- Examine the functionalities offered by digital solutions in metabolomics.
- Investigate stakeholder integrations and audience considerations within the metabolomics landscape.
- Explore thematic resonances and key priorities such as technology integration, patient-centricity, and personalized care.

STUDY METHODS

Systematic review of existing literature, market reports, and digital platforms related to metabolomics digital solutions. Data analysis methods encompass both quantitative and qualitative techniques, such as content and thematic analysis. For financial data, a subscription-based data portal was also utilized.

Data Collection:
- All data was mined from the sources (literature, market reports, and scholarly articles) in a specified format
- All company data from subscription-based databases was also collected based on a pre-defined template.
- The templates are designed by HITLAB researchers to mine for data to meet the objectives of the study.

Data Analysis:
- Quantitative analysis to calculate percentages and descriptive summary measures.
- Qualitative analysis included content and thematic analysis on features and functions of each metabolomics solution.

STUDY RESULTS

A total of 26 companies were included in this landscape, and a total of 27 metabolomics solutions were analysed in detail.

Geographical insights:

California is a leading hub with 33% of the companies based there, followed by Pennsylvania at 29%, Illinois, Alberta and North Carolina at 7% each and Massachusetts, Colorado, Georgia, Wisconsin at 3% each.

US State wide distribution of companies

Funding insights:

The total funding for the health and biotech companies is $8.15 billion, with individual funding ranging from $0.26 million to $2.1 billion. The average funding per company is $313.44 million, and the median funding is $40 million.

Companies receiving Grants funding averaged 5 funding rounds with an average of 9.5 investors, whereas those secured through Venture funding had an average of 4 rounds with 11.75 investors. Notably, Series B and Seed stage companies averaged 3 rounds each, with 3.5 and 3 investors, respectively.

Solution Formulations:

Majority companies (29%) offer their solutions as assays. A notable portion (15%) focuses on integrating assay with an algorithm or a mobile application or a digital device that are AI-powered and serve specific functionalities.

Disease Indications:

There is a wide variety of disease indications that are addressed by the studied solutions. Majority solutions (26%) target multiple types of cancers, followed by 7% dedicated to a specific disease type such as cardiovascular and respiratory diseases, and 5% dedicated to diabetes, gastrointestinal and infectious diseases.

Content and Thematic Analysis:

Results from Content Analysis
Content analysis identified *'data' [11], 'testing'[9], 'care'[8], 'blood'[7], 'platform' [7], 'sequencing' [7],* and *'cancer' [7]* as the most frequent words in the features and functions across the landscape. This emphasizes the solutions' focus on being data-driven, blood-based testing platforms aiding healthcare.

Features and Functions - Key Themes
Integrated healthcare solutions, precision cancer care, innovative diagnostic techniques, respiratory health solutions, accelerated testing and results

TOPIC MODELLING OF FEATURES AND FUNCTIONS

Detecting and addressing a wide range of health issues through advanced support and assistance.

Focus on molecular diagnostics for accurate and early disease detection.

Monitoring and analyzing cellular activity, expression, and markers for effective treatment.

Development of high-throughput data platforms for efficient data processing.

Personalized medicine approaches tailored to individual patient needs.

Emphasis on rapid diagnostic tests and molecular diagnostics for immunoassays.

Exploration of methods for measuring molecular components for precision medicine.

Decision-making tests for effective management of diabetes and related health issues.

CONCLUSIONS

- Metabolomics and diagnostics are experiencing a digital transformation, reshaping disease detection and diagnosis.
- Through the examination of 27 digital solutions from 26 companies, we have provided a detailed overview of market trends, functionalities, and stakeholder integration within this evolving landscape.
- Our findings underscore the predominance of the U.S.-based market, with California emerging as the leader, closely followed by Pennsylvania.
- The solutions offered predominantly focus on assays, with a significant emphasis on identifying or detecting specific molecules, particularly targeting multiple cancers.
- Our exploration of key themes through topic modeling highlights areas such as Integrated Healthcare Solutions, Precision Cancer Care, Innovative Diagnostic Technologies, Respiratory Health Solutions, and Accelerated Testing and Results.

HITLAB
3960 Broadway, Suite 501
New York, NY 10032
Phone: 212-543-0100
Email: research@hitlab.org

HITLAB
Healthcare Innovation Technology

METFORA DIAGNOSTICS